Also trades as: NUVB-WT (NYSE) · $vol 0M
NUVB NYSE
Nuvation Bio Inc.
1W: -4.6%
1M: -18.8%
3M: -31.0%
YTD: -47.0%
1Y: -6.2%
3Y: +288.9%
5Y: -53.7%
$4.55
+0.04 (+0.89%)
Weekly Expected Move ±6.9%
$4
$4
$5
$5
$5
Credit Risk of going bust: higher than 72% of companies Debt: 13.7% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the third-riskiest tenth, about 1 in 140 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.11 (down 98%), Nuvation Bio Inc. would be worth roughly what it owes.
Total debt $252.1M against a stock market value of $1.59B.
Distance to default 3.24 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $128.2M (short-term plus half of long-term), stock volatility 78.8%; Altman Z'' -0.12. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.11 (down 98%), Nuvation Bio Inc. would be worth roughly what it owes.
Total debt $252.1M against a stock market value of $1.59B.
Distance to default 3.24 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $128.2M (short-term plus half of long-term), stock volatility 78.8%; Altman Z'' -0.12. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
8 relationships8
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2024-03-25
Earliest Filing
2026-01-12
Latest Filing
partner: 4
supplier: 2
target: 2
Counterparties (Filed by NUVB)
8 relationshipsCompanies named in NUVB's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Eisai Co., Ltd. | — | partner | Exclusive license and collaboration agreement for taletrectinib in multiple territories. | 2026-01-12 | View |
| Asymchem Life Science (Tianjin) Co., Ltd. | — | supplier | Commercial supply agreement for taletrectinib drug product | 2025-03-25 | View |
| Asymchem Laboratories (Tianjin) Co., Ltd. | — | supplier | Commercial supply agreement for taletrectinib drug substance | 2025-03-05 | View |
| AnHeart Therapeutics, Ltd. | — | target | Target company acquired by Nuvation Bio Inc. in a merger transaction. | 2024-04-10 | View |
| Artemis Merger Sub I, Ltd. | — | partner | Wholly owned subsidiary of Nuvation Bio Inc. used as a party in the merger agreement. | 2024-04-10 | View |
| Artemis Merger Sub II, Ltd. | — | partner | Wholly owned subsidiary of Nuvation Bio Inc. used as a party in the merger agreement. | 2024-04-10 | View |
| Continental Stock Transfer & Trust Company | — | partner | Acted as warrant agent for the amended and restated warrant agreement. | 2024-04-10 | View |
| AnHeart Therapeutics Ltd. | — | target | Target company in a merger agreement with Nuvation Bio Inc. | 2024-03-25 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-06 | Earnings Release; Exhibits | View | |
| 2026-07-06 | Financial Obligation; Other Events; Exhibits | View | |
| 2026-06-30 | Material Agreement; Termination of Agreement; Financial Obligation; Other Events; Exhibits | Agreement | View |
| 2026-05-27 | Shareholder Vote | View | |
| 2026-05-04 | Earnings Release; Exhibits | View | |
| 2026-03-02 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-12 | Entry into Material Definitive Agreement; Results of Operations and Financial Condition; Regulation | Agreement | View |
| 2025-11-26 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-11-17 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-11-03 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-11 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-05-23 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-03-25 | Entry into Material Definitive Agreement | Agreement | View |
| 2025-03-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-03-05 | Entry into Material Definitive Agreement | Agreement | View |
| 2025-03-04 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation | Agreement | View |
| 2025-02-12 | Departure/Election of Directors; Appointment of Officers | View | |
| 2024-11-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR